A new flu treatment could drastically reduce one of flu’s deadliest complications—bacterial pneumonia—by helping the lungs defend themselves, rather than targeting the virus directly. Influenza specialist Associate Professor Michelle Tate’s latest research has shown that a synthetic peptide called LAT9997, delivered directly into the airway, can protect against both severe flu and the secondary bacterial infections that frequently follow it—often with fatal consequences.
This article was originally published on MedicalXpress.com
